GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » Capex-to-Revenue

Oncimmune Holdings (LSE:ONC) Capex-to-Revenue : 0.00 (As of Aug. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Oncimmune Holdings's Capital Expenditure for the six months ended in Aug. 2024 was £-0.01 Mil. Its Revenue for the six months ended in Aug. 2024 was £1.55 Mil.

Hence, Oncimmune Holdings's Capex-to-Revenue for the six months ended in Aug. 2024 was 0.00.


Oncimmune Holdings Capex-to-Revenue Historical Data

The historical data trend for Oncimmune Holdings's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings Capex-to-Revenue Chart

Oncimmune Holdings Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 Aug23 Aug24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.29 0.13 0.03 -

Oncimmune Holdings Semi-Annual Data
Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Feb23 Aug23 Feb24 Aug24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 0.02 0.21 - -

Competitive Comparison of Oncimmune Holdings's Capex-to-Revenue

For the Biotechnology subindustry, Oncimmune Holdings's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncimmune Holdings's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's Capex-to-Revenue falls into.


;
;

Oncimmune Holdings Capex-to-Revenue Calculation

Oncimmune Holdings's Capex-to-Revenue for the fiscal year that ended in Aug. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.009) / 2.739
=0.00

Oncimmune Holdings's Capex-to-Revenue for the quarter that ended in Aug. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.005) / 1.553
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncimmune Holdings  (LSE:ONC) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Oncimmune Holdings Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncimmune Holdings Business Description

Traded in Other Exchanges
N/A
Address
1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacturing, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.